First-in-human study of CDNF in patients with Parkinson's disease

Trial Profile

First-in-human study of CDNF in patients with Parkinson's disease

Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs CDNF (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 12 Jun 2017 According to a Herantis Pharma media release,The participating patients will also be offered the possibility to participate in an extension study.
    • 12 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017, according to a Herantis Pharma media release.
    • 12 Jun 2017 According to a Herantis Pharma media release, The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, Sweden.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top